Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma

Bookmark and Share
Published: 16 Jun 2020
Views: 93
Rating:
Save
Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

Prof John Kuruvilla speaks to ecancer about the results from the KEYNOTE-204 trial that were presented at the ASCO 2020 Virtual Meeting.

The phase III trial was a randomised, open-label study of pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin lymphoma.

Prof Kuruvilla reports that pembrolizumab had a statistically significant and clinically meaningful improvement in progression-free survival.